Relay Therapeutics Q2 2026 net loss $83.7M; cash $910.9M; selected zovegalisib triplet for 1L breast cancer

Relay Therapeutics, Inc.

Net loss $83.7M ($0.41/sh) vs $70.4M ($0.41/sh) in Q2 2025; R&D expenses rose to $76.5M.
Cash $910.9M at June 30, 2026, up from $642.1M at March 31, 2026, after $316M follow-on offering in May 2026.
Selected zovegalisib + atirmociclib + endocrine therapy as 1L breast cancer triplet; Phase 3 trial expected early 2027.
Initial ReInspire data: 60% volumetric response at 12 weeks in vascular anomalies; expansion cohorts opened.
ATM offering capacity increased to $462.978M; $162.978M already sold under prior $250M program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.